Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Buy and raises the price target from $287 to $300.